The Food and Drug Administration has issued an alert concerning two glucose monitors with a “high-risk” sensor issue. Abbott Diabetes Care initiated a “medical device correction” on Nov. 24, for ...
ACTON, Mass., November 20, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
A newly issued alert links certain FreeStyle Libre 3 and 3 Plus glucose-monitoring sensors to at least seven deaths and hundreds of serious injuries.
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
WASHINGTON — Malfunctioning glucose sensors used by millions of people with diabetes have been tied to more than 700 serious injuries and seven deaths worldwide, according to new information released ...
Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
A subset of FreeStyle Libre 3 and Libre 3 Plus sensors can give falsely low glucose readings, with 736 serious adverse events and seven deaths reported worldwide. Only specific Libre 3 and Libre 3 ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback